Ann: GENERAL: PEB: Outperformance confirmed from combined use of Cxbladder, page-2

The weight of evidence is growing. Being published with this sort of clinical utility as pretty huge. This publication is the Rolling Stones magazine of urology IMO.

for those stats boffins (or ones that have researched COVID vaccine efficacy) you will realise those results are impressive and combined with the clinical utility angle (minimising hospital resources with low risk) I see that in 5 years this will be be the standard of care that will be employed in the majority of hospitals globally!

why are they focusing at n the US? Because that is where the money is. For $750 us per test, that is where the market cap is.